Novavax said yesterday it will manufacture its COVID-19 vaccine in Canada after the country’s health regulator allowed its use in children aged between 12 and 17 years as a primary series of shots.
Production of test batches of the protein-based vaccine, Nuvaxovid, will begin at the Montreal manufacturing centre by early 2023, the company said.
The agency’s approval was based on a late-stage study which showed the vaccine was effective against COVID-19 in children aged between 12 and 17 years.
Earlier this year, the Canadian health regulator had allowed the use of Novavax’s vaccine for primary series and as a booster in adults above 18 years of age.
Hurt by a global supply glut in COVID-19 vaccine and waning demand, Novavax cut its full-year revenue forecast last month to a range of $2 billion and $2.3 billion. Shots from rivals Pfizer/BioNtech and Moderna were approved last year for initial vaccination of adolescents in Canada, hurting the vaccine maker further.
Edits by EP News Bureau
Your blog is very informative. thanks for Sharing this blog.